ArticleJACC. Case reports2025
Refractory Coronary Vasospasms in a Patient With Eosinophilic Granulomatosis With Polyangiitis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do Not Overlook the Existence of Specific Coronary Spasms, Which Are Often Juvenile and Refractory: Eosinophilia-associated Coronary Spasm.Internal medicine (Tokyo, Japan) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary vasospasms refractory to calcium channel blockers and nitrates may be secondary to a systemic process. Although rare, eosinophilic granulomatosis with polyangiitis (EGPA) can cause coronary vasospasms. CASE SUMMARY: A 33-year-old woman presented with recurrent chest pain leading to multiple episodes of cardiac arrest. Rising eosinophilia and coronary intimal thickening were noted, and cardiac magnetic resonance imaging showed scarring. Owing to the high index of suspicion for EGPA, she was started on steroid therapy and cyclophosphamide. With this treatment, she had no further episodes of cardiac symptoms. DISCUSSION: Cardiac involvement in EGPA is rare and carries a poor prognosis. The most common cardiac manifestations are congestive heart failure, pericarditis, myocarditis, and arrhythmias. TAKE-HOME MESSAGES: EGPA should be considered in the differential diagnosis for patients with refractory coronary vasospasms and eosinophilia >10%. EGPA cannot be ruled out solely based on the absence of antineutrophil cytoplasmic antibodies, particularly in patients with cardiac involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.